Rahul Kumar
Cited by
Cited by
In Silico Approach for Predicting Toxicity of Peptides and Proteins
S Gupta, P Kapoor, K Chaudhary, A Gautam, R Kumar, ...
PloS one 8 (9), e73957, 2013
In silico approaches for designing highly effective cell penetrating peptides
A Gautam, K Chaudhary, R Kumar, A Sharma, P Kapoor, A Tyagi, ...
Journal of translational medicine 11, 1-12, 2013
In Silico Models for Designing and Discovering Novel Anticancer Peptides
A Tyagi, P Kapoor, R Kumar, K Chaudhary, A Gautam, GPS Raghava
Scientific reports 3 (1), 2984, 2013
CPPsite: a curated database of cell penetrating peptides
A Gautam, H Singh, A Tyagi, K Chaudhary, R Kumar, P Kapoor, ...
Database 2012, bas015, 2012
TumorHoPe: a database of tumor homing peptides
P Kapoor, H Singh, A Gautam, K Chaudhary, R Kumar, GPS Raghava
PLoS One 7 (4), e35187, 2012
CancerDR: cancer drug resistance database
R Kumar, K Chaudhary, S Gupta, H Singh, S Kumar, A Gautam, P Kapoor, ...
Scientific reports 3 (1), 1445, 2013
An in silico platform for predicting, screening and designing of antihypertensive peptides
R Kumar, K Chaudhary, J Singh Chauhan, G Nagpal, R Kumar, ...
Scientific reports 5 (1), 12512, 2015
Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome
AB Holmes, C Corinaldesi, Q Shen, R Kumar, N Compagno, Z Wang, ...
Journal of Experimental Medicine 217 (10), e20200483, 2020
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas
FC Geyer, A Li, AD Papanastasiou, A Smith, P Selenica, KA Burke, ...
Nature communications 9 (1), 1816, 2018
Peptide toxicity prediction
S Gupta, P Kapoor, K Chaudhary, A Gautam, R Kumar, GPS Raghava
Computational Peptidology, 143-157, 2015
Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial
N Riaz, E Sherman, X Pei, H Schöder, M Grkovski, R Paudyal, N Katabi, ...
JNCI: Journal of the National Cancer Institute 113 (6), 742-751, 2021
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors
F Pareja, AH Brandes, T Basili, P Selenica, FC Geyer, D Fan, ...
Nature Communications 9 (1), 3533, 2018
The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers
B Weigelt*, R Bi*, R Kumar*, P Blecua, DL Mandelker, FC Geyer, F Pareja, ...
JNCI: Journal of the National Cancer Institute 110 (9), 1030-1034, 2018
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells
J Nikkilä, R Kumar, J Campbell, I Brandsma, HN Pemberton, F Wallberg, ...
British journal of cancer 117 (1), 113-123, 2017
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
I Bajrami, R Marlow, M van de Ven, R Brough, HN Pemberton, J Frankum, ...
Cancer Discovery 8 (4), 498-515, 2018
Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics
A Gautam, P Kapoor, K Chaudhary, R Kumar, GPS Raghava, ...
Current medicinal chemistry 21 (21), 2367-2391, 2014
Computational approach for designing tumor homing peptides
A Sharma, P Kapoor, A Gautam, K Chaudhary, R Kumar, JS Chauhan, ...
Scientific reports 3 (1), 1607, 2013
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB‐NFIB fusion gene
J Kim, FC Geyer, LG Martelotto, CKY Ng, RS Lim, P Selenica, A Li, ...
The Journal of pathology, 2017
The genomic landscape of mucinous breast cancer
F Pareja, JY Lee, DN Brown, S Piscuoglio, R Gularte-Mérida, P Selenica, ...
JNCI: Journal of the National Cancer Institute 111 (7), 737-741, 2019
Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression
CW Ashley, ADC Paula, R Kumar, D Mandelker, X Pei, N Riaz, ...
Gynecologic oncology 152 (1), 11-19, 2019
The system can't perform the operation now. Try again later.
Articles 1–20